Literature DB >> 16244813

Motor dysfunction in patients with liver cirrhosis: impairment of handwriting.

Sergei Mechtcheriakov1, Ivo W Graziadei, André Kugener, Ingrid Schuster, Joerg Mueller, Hartmann Hinterhuber, Wolfgang Vogel, Josef Marksteiner.   

Abstract

Motor dysfunction is an important clinical finding in patients with liver cirrhosis and mild forms of hepatic encephalopathy. The mechanisms and clinical appearance of motor impairment in patients with liver cirrhosis are not completely understood. We studied fine motor control in forty four patients with advanced liver cirrhosis (excluding those with hepatic encephalopathy grade II) and 48 healthy controls using a kinematic analysis of standardized handwriting tests. We analysed parameters of velocity, the ability to coordinate and the level of automatisation of handwriting movements. Furthermore, we studied the association between impairment of handwriting and clinical neuro-psychiatric symptoms. As compared with control subjects, patients showed a statistically significant reduction of movement peak velocity in all handwriting tasks as well as a substantial increase of number of velocity inversions per stroke. Using a z-score based assessment we found impairment of handwriting in fourteen out of forty four patients (31.8 %). The deterioration of handwriting was associated with clinical symptoms of motor dysfunction, such as bradykinesia, adiadochokinesia, dysmetria of upper extremities and gait ataxia. This is the first study that quantitatively investigates impairment of handwriting in patients with liver cirrhosis. Our findings suggest the application of kinematic analysis of handwriting for diagnostics of motor dysfunction in patients with mild forms of hepatic encephalopathy.

Entities:  

Mesh:

Year:  2005        PMID: 16244813     DOI: 10.1007/s00415-005-0995-5

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  37 in total

1.  Cortical origin of mini-asterixis in hepatic encephalopathy.

Authors:  L Timmermann; J Gross; G Kircheis; D Häussinger; A Schnitzler
Journal:  Neurology       Date:  2002-01-22       Impact factor: 9.910

2.  Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis.

Authors:  A Das; R K Dhiman; V A Saraswat; M Verma; S R Naik
Journal:  J Gastroenterol Hepatol       Date:  2001-05       Impact factor: 4.029

3.  High prevalence of sleep disturbance in cirrhosis.

Authors:  J Córdoba; J Cabrera; L Lataif; P Penev; P Zee; A T Blei
Journal:  Hepatology       Date:  1998-02       Impact factor: 17.425

4.  Attention deficits in minimal hepatic encephalopathy.

Authors:  K Weissenborn; S Heidenreich; J Ennen; N Rückert; H Hecker
Journal:  Metab Brain Dis       Date:  2001-06       Impact factor: 3.584

5.  Relationship between cerebral perfusion in frontal-limbic-basal ganglia circuits and neuropsychologic impairment in patients with subclinical hepatic encephalopathy.

Authors:  A M Catafau; J Kulisevsky; L Bernà; J Pujol; J C Martin; P Otermin; J Balanzó; I Carrió
Journal:  J Nucl Med       Date:  2000-03       Impact factor: 10.057

6.  Screening of subclinical hepatic encephalopathy.

Authors:  M Groeneweg; W Moerland; J C Quero; W C Hop; P F Krabbe; S W Schalm
Journal:  J Hepatol       Date:  2000-05       Impact factor: 25.083

7.  Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998.

Authors:  Peter Ferenci; Alan Lockwood; Kevin Mullen; Ralph Tarter; Karin Weissenborn; Andres T Blei
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

8.  Consistency of handwriting movements in dementia of the Alzheimer's type: a comparison with Huntington's and Parkinson's diseases.

Authors:  M J Slavin; J G Phillips; J L Bradshaw; K A Hall; I Presnell
Journal:  J Int Neuropsychol Soc       Date:  1999-01       Impact factor: 2.892

9.  Cerebral 1H MR spectroscopy and neuropsychologic status of patients with hepatic encephalopathy.

Authors:  M A Thomas; A Huda; B Guze; J Curran; M Bugbee; L Fairbanks; Y Ke; T Oshiro; P Martin; F Fawzy
Journal:  AJR Am J Roentgenol       Date:  1998-10       Impact factor: 3.959

10.  Effects of sertraline on kinematic aspects of hand movements in patients with obsessive-compulsive disorder.

Authors:  Roland Mergl; Paraskevi Mavrogiorgou; Georg Juckel; Michael Zaudig; Ulrich Hegerl
Journal:  Psychopharmacology (Berl)       Date:  2003-08-30       Impact factor: 4.530

View more
  6 in total

1.  Ataxia and middle cerebellar peduncle lesions in hepatic encephalopathy.

Authors:  Ryuichi Furukawa; Ryuji Sakakibara; Nobuo Hosoe; Masahiko Kishi; Emina Ogawa; Yasuo Suzuki
Journal:  Neuroradiology       Date:  2009-03-04       Impact factor: 2.804

2.  Activation of neuronal nitric oxide synthase in cerebellum of chronic hepatic encephalopathy rats is associated with up-regulation of NADPH-producing pathway.

Authors:  Santosh Singh; Surendra K Trigun
Journal:  Cerebellum       Date:  2010-09       Impact factor: 3.847

3.  Aberrant Resting-State Functional Connectivity Density in Patients with Hepatitis B Virus-Related Cirrhosis.

Authors:  Xiao-Fei Lv; Hua-Wang Wu; Li Tian; Lu-Jun Han; Jing Li; Ying-Wei Qiu; Gui-Hua Jiang; Xue-Lin Zhang; Rong Zhang; Chuan-Miao Xie
Journal:  Biomed Res Int       Date:  2016-06-14       Impact factor: 3.411

4.  Golexanolone, a GABAA receptor modulating steroid antagonist, restores motor coordination and cognitive function in hyperammonemic rats by dual effects on peripheral inflammation and neuroinflammation.

Authors:  Gergana Mincheva; Carla Gimenez-Garzo; Paula Izquierdo-Altarejos; Mar Martinez-Garcia; Magnus Doverskog; Thomas P Blackburn; Anneli Hällgren; Torbjörn Bäckström; Marta Llansola; Vicente Felipo
Journal:  CNS Neurosci Ther       Date:  2022-07-26       Impact factor: 7.035

5.  Enhanced BDNF and TrkB Activation Enhance GABA Neurotransmission in Cerebellum in Hyperammonemia.

Authors:  Yaiza M Arenas; Mar Martínez-García; Marta Llansola; Vicente Felipo
Journal:  Int J Mol Sci       Date:  2022-10-04       Impact factor: 6.208

6.  Bacopa monnieri Extract (CDRI-08) Modulates the NMDA Receptor Subunits and nNOS-Apoptosis Axis in Cerebellum of Hepatic Encephalopathy Rats.

Authors:  Papia Mondal; Surendra Kumar Trigun
Journal:  Evid Based Complement Alternat Med       Date:  2015-08-27       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.